January 2025 in “Journal of Pharmacognosy and Phytochemistry” Vitex negundo has potential health benefits, including anti-inflammatory and anti-cancer effects.
22 citations
,
September 2024 in “Chemical Engineering Journal” A new microneedle patch effectively and safely treats alopecia areata.
18 citations
,
August 2015 in “Biochemical and Biophysical Research Communications” XEDAR triggers a specific signaling pathway in cells.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Tridax procumbens is a promising herb for developing safe, affordable plant-based medicines.
15 citations
,
July 2004 in “AIDS” Indinavir therapy can cause reversible skin, hair, and nail darkening.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
10 citations
,
June 2018 in “Aaps Pharmscitech” The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.
December 2024 in “International Journal of Drug Delivery Technology” The new delivery method for dutasteride is more effective and has fewer side effects.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
10 citations
,
October 2018 in “Dermatologic Therapy” The lotion with equol, dihomo-γ-linolenic acid, and propionyl-l-carnitine was effective in reducing hair loss in men and women.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
November 1998 in “European Neuropsychopharmacology” July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
January 2024 in “JAAD case reports” Netherton syndrome can cause severe and chronic vulvovaginal symptoms that may improve with continuous oral contraceptives.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
1 citations
,
July 2020 in “The Egyptian Journal of Hospital Medicine” The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.
May 2018 in “Journal of Clinical Oncology” The treatment is safe and shows promise for metastatic breast cancer.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.